Microsaic Regulatory News (MSYS)

21 June 2018

Microsaic Systems plc

("Microsaic" or the "Company")

Distribution Agreement with Amedis, spol. s ro.

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that it has signed a distribution agreement with Amedis, spol. s ro. ("Amedis"). Amedis will be the exclusive distributor of Microsaic-branded 4500 MiD® MS detectors in Slovakia.

Founded in 1991, Amedis distributes and provides application and service support for global brands across a wide range of technologies, including Liquid Chromatography Mass Spectrometry ("LCMS"), Inductively Coupled Plasma Mass Spectrometry ("ICPMS"), Gas Chromatography Mass Spectrometry ("GCMS") and Nuclear Magnetic Resonance ("NMR"). Additionally, Amedis has expertise in medical technologies, such as Linear Accelerators, Medical Imaging and Dosimetry for Radiation Therapy.

Glenn Tracey, CEO of Microsaic, commented, "Amedis is the perfect partner to distribute our compact, point of need MS technology, already having an impressive technology portfolio, unrivaled technical expertise, and full understanding of end user applications.

"Central Europe has shown impressive growth and opportunity for scientific instrumentation in recent years, and this agreement supports our growth strategy with select partners across the European region."

Milos Sebedinsky, CEO of Amedis, added: "Amedis appreciates the possibility to widen its product portfolio with the top quality Microsaic product range, especially in the field of flash chromatography purification. Our plan also is to integrate 4500 MiD® with High Performance Liquid Chromatography systems we are selling, as a complement to other detectors."

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.